Circulating SARS-CoV-2 variants B.1.1.7, 501Y.V2, and P.1 have gained ability to utilize rat and mouse Ace2 and altered in vitro sensitivity to neutralizing antibodies and ACE2-Ig

Here, we first investigated cross-species receptor usage of multiple SARS-CoV-2 variants that emerged during the pandemic.  More...